Details for Patent: 8,492,441

Which drugs does patent 8,492,441 protect, and when does it expire?

Patent 8,492,441 protects MAYZENT and is included in one NDA.

This patent has forty-seven patent family members in thirty-four countries.

Summary for Patent: 8,492,441

Title:	Dosage regimen of an S1P receptor agonist
Abstract:	S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
Inventor(s):	Legangneux; Eric (Basel, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	12/655,049
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,492,441

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-001	Mar 26, 2019		RX	Yes	No						A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-003	Aug 24, 2021		RX	Yes	No						A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-002	Mar 26, 2019		RX	Yes	Yes						A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE

Foreign Priority and PCT Information for Patent: 8,492,441

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	09167209	Aug 4, 2009

International Family Members for US Patent 8,492,441

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	074825
Australia	2009331582
Brazil	PI0923213